Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...
A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and ...
The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.
Bexotegrast-treated patients demonstrated improvements in forced vital capacity (FVC) and reduced cough severity compared to placebo. Bexotegrast was well tolerated at 160 mg over 12 weeks of ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Following use of race-neutral lung function equations, African American and Latino pediatric ...
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID 1) and deupirfenidone 825 mg TID and successfully demonstrated ...
Race-neutral equations for assessing lung function appeared to catch more true-abnormal findings for Black patients than did previously standard race-adjusted spirometry equations, a study showed.
Having low lung function as a middle-aged smoker without airway obstruction raised the likelihood for all-cause mortality, ...
If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback